Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium

JAN LOOCK, PETER LAMPRECHT and WOLFGANG L. GROSS
The Journal of Rheumatology March 2012, 39 (3) 658-659; DOI: https://doi.org/10.3899/jrheum.111083
JAN LOOCK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: loock.rostock@freenet.de
PETER LAMPRECHT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WOLFGANG L. GROSS
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

Mycophenolate is one of the mainstays of immunosuppressive therapy after organ transplantation and has also been increasingly used in the treatment of rheumatic diseases1. It is applied either as mycophenolate mofetil (MMF) or its enteric coated formulation (mycophenolate sodium; MPS). The immunosuppressive action of mycophenolate is mainly based on the inhibition of the de novo purine biosynthesis required for the proliferation of T and B lymphocytes2.

We describe a 72-year-old man with a 35-year history of seropositive rheumatoid arthritis (RA). During his disease course he had received multiple disease-modifying antirheumatic treatments (DMARD), which were either ineffective (chloroquine, sulfasalazine, gold) or discontinued because of adverse effects or contraindications (methotrexate, leflunomide). In 2007, the course had been complicated by an infected hip replacement with sepsis and secondary aortic valve endocarditis. A steady decline of his renal function (creatinine clearance 20 ml/min) was attributed to systemic amyloidosis. In September 2010, DMARD treatment with azathioprine was switched to MPS because of toxic bone marrow damage. Shortly thereafter, he developed severe migrating pains in rapidly altering locations together with a severe decline of general status. An increase of the daily glucocorticoid dose (from 5 to 10 mg prednisolone daily) did not alter the symptoms. He was finally admitted to our service in a severely compromised general state and complaining of severe, immobilizing pain and marked tenderness to palpation at multiple discrete periarticular points very atypical of a synovitic cause and without clinical or sonographic signs of synovitis.

Laboratory values showed an increased erythrocyte sedimentation rate (ESR) of 110 mm/h and C-reactive protein (CRP) 57 mg/l (normal < 5 mg/l). An elevated serum procalcitonin (PCT) and subfebrile temperatures to 38°C were present. Intensive investigations including blood and urine cultures, transesophageal echocardiography, endoscopy of the upper gastrointestinal tract, skeletal scintigraphy, ear-nose-throat and dentistry consult, synovial analysis of replaced joints (given the history of infected joint replacement in this patient), and positron-emission tomography combined with computed tomography of the whole body did not reveal an infectious focus or neoplastic disease. Similarly, no evidence of a viral infection (cytomegalovirus, Epstein-Barr virus, hepatitis B and C, human immunodeficiency virus) or of active rheumatic disease was found. Finally, considering the close temporal relationship of symptom onset to initiation of MPS, an MPS-induced acute inflammatory syndrome was suspected. MPS discontinuation was followed by prompt and complete disappearance of all symptoms within 1 day, accompanied by rapid normalization of ESR, CRP, and decline of the PCT level (Figure 1). The patient decidedly rejected a reexposure to mycophenolate (either to MPS or MMF). He was discharged a few days later without further intervention and since then has been seen regularly as an outpatient for as long as 7 months, reporting lasting well-being under monotherapy with low-dose prednisolone.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Time course of levels of serum C-reactive protein (CRP; normal < 5 mg/l) and procalcitonin (PCT; normal < 0.1 ng/ml). Vertical lines represent initiation and discontinuation of mycophenolate sodium (MPS). After 2 weeks, the MPS dose had been increased from 360 mg to 720 mg twice daily. Arrows represent times of readmission and discharge from hospital. No laboratory data were available from the time between MPS initiation and readmission.

To our knowledge, this report (being 1 of only 4 case descriptions of an acute inflammatory syndrome attributable to mycophenolate) is the first in which the reaction is due to intake of MPS. Further, it is also the first description in a patient with RA. Four other patients have been reported: 2 with granulomatosis with polyangiitis (Wegener’s), one after renal transplant, and one with systemic lupus erythemodes3,4,5. The symptoms described in those cases were very similar to those in our patient. All other patients had received MMF, and 2 of them showed identical symptoms after reexposure to the drug. The mechanism by which mycophenolate induces an acute inflammatory response in some individuals remains obscure. Ex vivo stimulation in the presence of mycophenolate induces paradoxically increased oxidative bursts in neutrophils of affected patients5. Moreover, mycophenolate acyl glucuronide metabolite concentrations correlate with serum interleukin 6 (IL-6) levels in patients with the acute inflammatory syndrome3. In our patient, a severe renal insufficiency could have contributed to the observed adverse reaction by an impaired excretion of a responsible agent.

We show for the first time that PCT levels are also elevated during MPS-associated acute inflammatory syndrome. PCT is an established marker of systemic inflammation in bacterial infection and sepsis and correlates with serum IL-6 levels6. Thus it can be speculated that mycophenolate metabolite-mediated IL-6 production induces elevated PCT serum levels in the acute inflammatory syndrome. Interestingly, increased PCT serum levels have also been described recently in patients with idiosyncratic inflammatory drug reactions to azathioprine and carbamazepine, and in the neuroleptic malignant syndrome7,8,9. Therefore, drug reactions should be considered in the differential diagnosis of inflammatory states with elevated PCT in rheumatic diseases.

The ability of mycophenolate to induce an acute inflammatory response appears to be rare and less appreciated than the similar systemic inflammatory reaction to azathioprine. However, awareness of the syndrome is important in routine clinical care, since discontinuation of the responsible agent results in prompt resolution of the symptoms.

REFERENCES

  1. 1.↵
    1. Appel GB,
    2. Radhakrishnan J,
    3. Ginzler EM
    . Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005;80 Suppl:S265–71.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Allison AC,
    2. Eugui EM
    . Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85–118.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Maes B,
    2. Oellerich M,
    3. Ceuppens JL,
    4. Armstrong VW,
    5. Evenepoel P,
    6. Kuypers D,
    7. et al.
    A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener’s granulomatosis. Nephrol Dial Transplant 2002;17:923–6.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hochegger K,
    2. Gruber J,
    3. Lhotta K
    . Acute inflammatory syndrome induced by mycophenolate mofetil in a patient following kidney transplantation. Am J Transplant 2006;6:852–4.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Konon I,
    2. Cronin ME,
    3. Ryan LM
    . Acute inflammatory syndrome following introduction of mycophenolate mofetil in a patient with systemic lupus erythematodes. Arthritis Rheum 2008;59:754–6.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Matzaraki V,
    2. Alexandraki KI,
    3. Venetsanou K,
    4. Piperi C,
    5. Myrianthefs P,
    6. Malamos N,
    7. et al.
    Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336–42.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Cabot B,
    2. Pautas E,
    3. Gatey M,
    4. Perivier S,
    5. Mahieux F,
    6. Pinquier C,
    7. et al.
    Increase of serum procalcitonin levels during a neuroleptic malignant syndrome. Ann Biol Clin 2009;67:697–700.
    OpenUrlPubMed
  8. 8.↵
    1. Bonaci-Nikolic B,
    2. Jeremic I,
    3. Nikolic M,
    4. Andrejevic S,
    5. Lavadinovic L
    . High procalcitonin in a patient with drug hypersensitivity syndrome. Intern Med 2009;48:1471–4.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Schinke S,
    2. Holle J,
    3. Gross WL
    . Hohe Procalcitonin-Spiegel bei Patienten mit Wegenerscher Granulomatose und Azathioprin-Fieber (High procalcitonin levels in patients with Wegener’s granulomatosis and azathioprine fever) [abstract]. Z Rheumatol 2010;69 Suppl 1:71.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium
JAN LOOCK, PETER LAMPRECHT, WOLFGANG L. GROSS
The Journal of Rheumatology Mar 2012, 39 (3) 658-659; DOI: 10.3899/jrheum.111083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium
JAN LOOCK, PETER LAMPRECHT, WOLFGANG L. GROSS
The Journal of Rheumatology Mar 2012, 39 (3) 658-659; DOI: 10.3899/jrheum.111083
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Herpes Zoster Vaccine and Rheumatoid Arthritis
  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire